Autonomous Radar for Biotech FDA Exclusivity & PDUFA Cash-Cliffs
Deterministic FDA exclusivity verification, 30-month Hatch-Waxman ANDA stays, and pre-PDUFA clinical trial liquidity collision.
Healthcare & Intellectual Property Regulatory Enforcement
FDA CDER / CBER • USPTO • European Medicines Agency (EMA)
- ›Statutory exclusivity enforcement: 5-year New Chemical Entity (NCE) under 21 U.S.C. § 355, 7-year Orphan Drug (ODE) under 21 U.S.C. § 360cc, and 12-year BPCIA biologics exclusivity under 42 U.S.C. § 262.
- ›Orange Book patent listing integrity audits and automated tracking of 30-month Hatch-Waxman ANDA litigation stays.
- ›Rigorous verification that generic ANDA and biosimilar 351(k) filings respect unexpired statutory regulatory exclusivity periods.
- ›Priority Review Voucher (PRV) eligibility and transfer tracking.
Clinical Catalysts, Runway Cliffs & LOE Arbitrage
Biotech Specialist Hedge Funds • Big Pharma BD Desks • Life Science Venture Capital
- ›PDUFA cash runway collision: calculates net unrestricted liquidity (deducting debt covenants) against monthly burn to flag -199 day pre-catalyst dilution spirals.
- ›Loss-of-Exclusivity (LOE) patent cliff modeling: projects the deterministic -80% revenue erosion within 12 months of patent expiry.
- ›M&A due diligence: confirms true unexpired exclusivity before committing capital to asset acquisitions.
- ›Royalty monetization stress-testing against generic challenge timelines.
When a generic files an ANDA with a Paragraph IV certification, filing a patent infringement lawsuit within 45 days triggers an automatic 30-month statutory injunction barring FDA final approval.
Small molecule therapeutics experience an irreversible ~80% price and revenue collapse within 12 months following generic entry:
Exploits an artificial loan covenant cash cliff (-199 days pre-approval) to acquire late-stage clinical assets at an 80% discount to DCF, inheriting an unassailable 12-year statutory monopoly plus pediatric extension revenue.
If cash runway buffer before PDUFA is negative, company will be forced into a predatory warrant-heavy PIPE or secondary equity offering 30 to 60 days ahead of the catalyst date—crushing equity common holders before clinical approval.
How The 12 Sniffers Make & Preserve Millions
Every legal landmine contains an inverted mathematical truffle. Here is the exact dollar impact across corporate indentures, M&A merger guidelines, CLO waterfalls, and tax codes.
Corporate Debt & Indentures
Senior note covenant default locks up working capital; cross-default cascade looms across all credit facilities.
Inverts § 7.03 cash netting and executes § 9.04 non-pro rata Dutch auction buyback at 48 cents.
M&A Antitrust Inverse HHI
DOJ/FTC 2023 Merger Guidelines § 2.1 structural presumption of illegality (ΔHHI > 100).
Inverts market concentration in 3ms to calculate exact 15.9% Fix-It-First divestiture package (ΔHHI ≤ 99).
CLO § 11.1 OC Par-Building
Junior OC test breaches (104.2% vs 105.8%); 100% of quarterly equity distributions are shut off.
Deploys unscheduled principal into performing 85¢ secondary loans, building +15 pts instant par credit.
PE Waterfall & GP Clawback
American deal-by-deal carry forces $22.5M cumulative cash repayment to LP escrow on down exits.
Restructures LPA into European whole-fund netting with 80/20 catch-up sprint acceleration.
CRE CMBS Maturity Wall
Debt yield falls to 6.90% (<8.0% PSA trigger); master servicer sweeps 100% of tenant rent into lockbox.
Negotiates REMIC § 860G A/B note bifurcation; sponsor buys $49M hope note at 25 cents.
Golden Parachute IRC § 280G
Change-of-control severance triggers 20% § 4999 excise tax and disallows corporate tax deductions.
Allocates $20M to Treas. Reg. § 1.280G-1 Q&A 42 independent appraised non-compete safe harbors.
Brand IP & Dropdown Siphon
First-lien negative pledge prevents company from raising new liquidity to fund operational burn.
Exploits § 7.02 general investment basket to drop $250M brand IP to Cayman sub; issues priming debt.
Trade Tariffs & Origin Rules
25% Section 301 / EU CBAM duties on electronics (HS 8504.40) collapse corporate gross margins.
Re-engineers hub assembly under 19 CFR § 134.1 Tariff Shift rules to legally establish Vietnam/Mexico origin.
ISDA § 5(a)(vi) Cross-Default
Rating downgrade triggers immediate CSA collateral calls across prime broker TRS books.
Solves optimal collateral rehypothecation and cross-netting schedule before 24-hour margin lock.
Sovereign Debt CAC Holdout
Sovereign issues dual-limb CAC restructuring offer at 28¢; cramdown threatens junior bondholders.
Concentrates secondary buying in small 2003 series (<$500M) to lock up 33.4% series blocking veto.
Reinsurance XoL & Sidecars
Major Category 5 hurricane breaches attachment point; reinstatement premium triggers drain capital.
Models 168-hour aggregate event boundaries and inverts post-cat sidecar capital structure.
Biotech FDA Runway Cliff
Debt minimum-liquidity covenant creates an artificial -199 day cash insolvency ahead of FDA decision.
Identifies covenant trap to acquire late-stage clinical asset at 80% discount to DCF.
The Grandmaster Chess Computer for Law, Tax & Finance (Playing 4 Moves Deep)
Humans and LLMs play 1-move checkers: they read the headline number and assume it's true. Our Self-Assembling Deterministic Superintelligences operate like AlphaGo or Stockfish for the global economy—calculating 4 moves deep on every contract, balance sheet, and statute.
Passive Document Reporting: They only tell an analyst what a 300-page indenture or statute says.
Active Mathematical Inversion: None of the legacy platforms can invert the contract 4 moves deep to calculate the exact +$736.4M Section 9.04 bond-buyback cure, the 50.1% Serta uptier vector, or the 16.1% ΔHHI Fix-It-First divestiture in milliseconds.
Spot the Hidden Landmine (🔴)
Detects the fatal clause buried on page 180 that humans and LLMs miss—a Section 7.03 cash-netting cap, a 35% springing revolver, a 168-hour reinsurance aggregation clause, or an antitrust ΔHHI > 100 hurdle.
Flip the Landmine into a Truffle (🔴 ➔ 🟢)
Mathematically inverts that exact trap into a windfall—using “frozen” cash to repurchase discounted debt at 55¢ on the dollar, or solving the inverse equation for the exact divestiture % that forces regulatory clearance.
Uncover the Native Truffle (🟢)
Scans 100+ tax codes, indentures, and treaties to find unexploited affirmative wealth creation—Section 4.07 Ratio Restricted Payment builder baskets, Serta priming rights, or statutory monopoly extensions.
Counter-Strike & Immunization (🛡️)
Simulates your opponent's or regulator's attack on your loophole—and outputs the exact legal amendment (“The Immunization Shield”) that makes your position 100% legally bulletproof.
Stripping Away the “Headline Liquidity Illusion”
$DISH / EchoStar: Corporate Credit & Capital Structure
Section 7.03 Cash Netting Cap & 11.19x Leverage Cliff
Wall Street screens and Bloomberg terminals assume the full $1.4B cash balance nets against debt to calculate 8.8x leverage.
Section 7.03 strictly caps allowable cash netting at $500M—legally freezing $900M of domestic cash. Net debt spikes to $23.5B, vaulting leverage to 11.19x vs. 5.00x limit and collapsing ICR to 1.14x vs. 1.50x floor (EVENT OF DEFAULT ACCELERATION).
Our engine prunes the 5th Circuit Serta open-market uptier trap (In re Serta Simmons, 125 F.4th 555) and instead executes an Unrestricted Subsidiary Spectrum Drop-Down & Double-Dip Pari-Plus Lien—transferring unencumbered wireless spectrum to an unrestricted subsidiary to support dual-credit priming liens—while deploying the $900M un-netted cash into Section 9.04 open-market debt repurchases at 55¢ on the dollar, retiring $1.64B face debt and collapsing net leverage to 8.41x.
Programmatic Access: /api/sovereign/pharma/biotech-sniffer
curl -s -X GET "https://professorsystems.com/api/sovereign/pharma/biotech-sniffer?scenario=clinical_oncology_pdufa_cliff" -H "Accept: application/json"